title: Role of Semen on Vaginal HIV-1 Transmission and Maraviroc Protection.
abstract: We used bone marrow/liver/thymus (BLT) humanized mice to establish the effect of semen on vaginal HIV infection and on the efficacy of topically applied maraviroc. Our results demonstrate that vaginal transmission of cell-free HIV occurs efficiently in the presence of semen and that topically applied maraviroc efficiently prevents HIV transmission in the presence of semen. We also show that semen has no significant effect on the transmission of transmitted/founder viruses or cell-associated viruses.
authors.affiliation: Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA.
authors.forename: Olivia D
authors.initials: OD
authors.lastname: Council
authors.affiliation: Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Swanson
authors.affiliation: Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA.
authors.forename: Rae Ann
authors.initials: RA
authors.lastname: Spagnuolo
authors.affiliation: Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA angela_wahl@med.unc.edu victor_garcia@med.unc.edu.
authors.forename: Angela
authors.initials: A
authors.lastname: Wahl
authors.affiliation: Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA angela_wahl@med.unc.edu victor_garcia@med.unc.edu.
authors.forename: J Victor
authors.initials: JV
authors.lastname: Garcia
mesh_terms: D000282:Administration, Intravaginal; D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology; D003510:Cyclohexanes / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D000077592:Maraviroc; D051379:Mice; D008822:Mice, Transgenic; D012661:Semen / Q000187:drug effects* / Q000821:virology; D014230:Triazoles / Q000494:pharmacology*; D014621:Vagina / Q000187:drug effects* / Q000276:immunology / Q000821:virology; D019562:Viral Load / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D003510:Cyclohexanes; D014230:Triazoles; D000077592:Maraviroc